Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine
Close
Advanced search
Site Map
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
403 0
SM ISO690:2012
BUTOV, Dmytro, LANGE, Christoph G., HEYCKENDORF, Jan, KALMYKOVA, Irina, BUTOVA, Tatyana, BOROVOK, N., NOVOKHATSKAYA, M., CHESOV, Dumitru. Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine. In: International Journal of Tuberculosis and Lung Disease, 2020, nr. 5(24), pp. 485-491. ISSN 1027-3719. DOI: https://doi.org/10.5588/ijtld.19.0508
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
International Journal of Tuberculosis and Lung Disease
Numărul 5(24) / 2020 / ISSN 1027-3719 /ISSNe 1815-7920

Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine
DOI:https://doi.org/10.5588/ijtld.19.0508

Pag. 485-491

Butov Dmytro1, Lange Christoph G.234, Heyckendorf Jan23, Kalmykova Irina5, Butova Tatyana6, Borovok N.5, Novokhatskaya M.5, Chesov Dumitru237
 
1 National Medical University of Kharkiv,
2 Research Center Borstel,
3 German Centre for Infection Research (DZIF), Partner Site Hamburg-Luebeck-Borstel-Riems,
4 Karolinska Institutet, Stockholm,
5 Kharkiv Regional Anti-Tuberculosis Dispensary No 1, Kharkiv,
6 V.N.Karazin Kharkiv Natsonal University,
7 ”Nicolae Testemițanu” State University of Medicine and Pharmacy
 
 
Disponibil în IBN: 19 martie 2021
Rezumat

OBJECTIVE: To document the level of drug resistance in MDR-TB patients and to characterize management capacities for their medical care and MDR-TB treatment outcomes in the Kharkiv region of Ukraine. This area has one of the highest frequencies of MDR-TB worldwide. METHODS: A retrospective observational cohort study was performed on registry data from the regional anti- TB dispensary in Kharkiv. All microbiologically confirmed MDR-TB patients registered in 2014 were included. Diagnostic, treatment and post-treatment follow-up data were analysed. RESULT S: Of 169 patients with MDR-TB, 55.0% had pre-extensively drug-resistant (pre-XDR) or XDR resistant patterns. Rapid molecular diagnosis by GeneXpert and liquid M. tuberculosis cultures were only available for 66.9% and 56.8% of patients, respectively. Phenotypic drug-susceptibility testing (DST) for high priority TB drugs (bedaquiline, linezolid, clofazimine) were not available. DST for later generation fluroquinolones was available only in 53.2% of patients. 50.9% of patients had less than 4 drugs in the treatment regimen proven to be effective by DST. More than 23.1% of patients with MDR-TB failed their treatment and only 45.0% achieved a cure. CONCLUS ION: The high prevalence of MDR-TB and poor MDR-TB treatment outcomes in the Kharkiv region, is associated with substantial shortages in rapid molecular and phenotypic DST, a lack of high priority MDR-TB drugs, poor treatment monitoring and followup capacities.
Cuvinte-cheie
management, MDR-TB, Outcome definitions, TBNET, Ukraine

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-124824</cfResPublId>
<cfResPublDate>2020-05-01</cfResPublDate>
<cfVol>24</cfVol>
<cfIssue>5</cfIssue>
<cfStartPage>485</cfStartPage>
<cfISSN>1027-3719</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/124824</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'>Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine</cfTitle>
<cfKeyw cfLangCode='EN' cfTrans='o'>management; MDR-TB; Outcome definitions; TBNET; Ukraine</cfKeyw>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>OBJECTIVE: To document the level of drug resistance in MDR-TB patients and to characterize management capacities for their medical care and MDR-TB treatment outcomes in the Kharkiv region of Ukraine. This area has one of the highest frequencies of MDR-TB worldwide. METHODS: A retrospective observational cohort study was performed on registry data from the regional anti- TB dispensary in Kharkiv. All microbiologically confirmed MDR-TB patients registered in 2014 were included. Diagnostic, treatment and post-treatment follow-up data were analysed. RESULT S: Of 169 patients with MDR-TB, 55.0% had pre-extensively drug-resistant (pre-XDR) or XDR resistant patterns. Rapid molecular diagnosis by GeneXpert and liquid M. tuberculosis cultures were only available for 66.9% and 56.8% of patients, respectively. Phenotypic drug-susceptibility testing (DST) for high priority TB drugs (bedaquiline, linezolid, clofazimine) were not available. DST for later generation fluroquinolones was available only in 53.2% of patients. 50.9% of patients had less than 4 drugs in the treatment regimen proven to be effective by DST. More than 23.1% of patients with MDR-TB failed their treatment and only 45.0% achieved a cure. CONCLUS ION: The high prevalence of MDR-TB and poor MDR-TB treatment outcomes in the Kharkiv region, is associated with substantial shortages in rapid molecular and phenotypic DST, a lack of high priority MDR-TB drugs, poor treatment monitoring and followup capacities.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-86827</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-55626</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-58257</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-86828</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-86829</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-86830</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-86831</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-24478</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfFedId>
<cfFedIdId>ibn-doi-124824</cfFedIdId>
<cfFedId>10.5588/ijtld.19.0508</cfFedId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
<cfFedId_Class>
<cfClassId>31d222b4-11e0-434b-b5ae-088119c51189</cfClassId>
<cfClassSchemeId>bccb3266-689d-4740-a039-c96594b4d916</cfClassSchemeId>
</cfFedId_Class>
<cfFedId_Srv>
<cfSrvId>5123451</cfSrvId>
<cfClassId>eda2b2e2-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>5a270628-f593-4ff4-a44a-95660c76e182</cfClassSchemeId>
</cfFedId_Srv>
</cfFedId>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-86827</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-86827-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Butov</cfFamilyNames>
<cfFirstNames>Dmytro</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-55626</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-55626-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Lange</cfFamilyNames>
<cfFirstNames>Christoph G.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-58257</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-58257-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Heyckendorf</cfFamilyNames>
<cfFirstNames>Jan</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-86828</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-86828-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Kalmykova</cfFamilyNames>
<cfFirstNames>Irina</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-86829</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-86829-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Butova</cfFamilyNames>
<cfFirstNames>Tatyana</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-86830</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-86830-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Borovok</cfFamilyNames>
<cfFirstNames>N.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-86831</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-86831-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Novokhatskaya</cfFamilyNames>
<cfFirstNames>M.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-24478</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-24478-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2020-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Chesov</cfFamilyNames>
<cfFirstNames>Dumitru</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfSrv>
<cfSrvId>5123451</cfSrvId>
<cfName cfLangCode='en' cfTrans='o'>CrossRef DOI prefix service</cfName>
<cfDescr cfLangCode='en' cfTrans='o'>The service of issuing DOI prefixes to publishers</cfDescr>
<cfKeyw cfLangCode='en' cfTrans='o'>persistent identifier; Digital Object Identifier</cfKeyw>
</cfSrv>
</CERIF>
Share

Institutul de Dezvoltare a Societatii InformationaleEXPERT on-lineInstitutul de Dezvoltare a Societatii InformationaleCN-2022Indicatori CDIASM

CC-BY-NC

Copyright © 2012 - 2024 Instrument Bibliometric National

Institutul de Dezvoltare a Societatii Informationale All Rights Reserved.

IBN v1.5.5

CSS valid!